2020… What a year ! Happy to start 2021 in the best conditions possible, announcing that TreeFrog Therapeutics signed 3 contracts in Q4 2020:
- We announced in November a partnership with the French Blood Agency (EFS) for the mass-production of iPS-derived HSC transplants
- 2 additional contracts with undisclosed big pharmas were signed in Q4 for the development of iPS-derived cell therapies.
More to come in 2021 